Stoke Mandeville Hospital is a large National Health Service (NHS) hospital located on the parish borders of Aylesbury and Stoke Mandeville, Buckinghamshire, England. It is managed by Buckinghamshire Healthcare NHS Trust. It was established in 1830 as a cholera hospital intentionally on the parish border between the neighbouring village of Stoke Mandeville and the town of Aylesbury to serve the residents of both settlements.The hospital's National Spinal Injuries Centre is one of the largest specialist spinal units in the world, and the pioneering rehabilitation work carried out there by Sir Ludwig Guttmann led to the development of the Paralympic Games. Mandeville, one of the official mascots for the 2012 Summer Olympics and Paralympics in London, was named in honour of the hospital's contribution to Paralympic sports.
Background Cosmetic surgery tourism has increased rapidly, with growing numbers of UK patients returning with complications requiring National Health Service (NHS) care. Limited regulation and inconsistent perioperative standards contribute to preventable harm.Objectives The aim of this study was to characterize the nature, severity, and causes of complications from overseas cosmetic surgery and estimate the resulting burden on the NHS.Methods A national retrospective study analyzed all 198 cases reported to the British Association of Aesthetic Plastic Surgeons (BAAPS) Cosmetic Tourism Complications Database between September 2022 and September 2024. Demographic, procedural, and clinical data were examined, and complications were graded using the BAAPS 5-stage classification.Results Patients were predominantly female (93%) with a mean age of 39 years; 76% had surgery in Turkey. Abdominoplasty (45%) was the most common procedure, followed by breast and liposuction surgeries. Frequent complications included wound dehiscence (37%), infection (28%), seroma (24%), and tissue necrosis (20%). Nearly half (48%) required operative management under general anesthesia, 28% minor procedures, and 4% intensive care; 1 death occurred from pulmonary embolism. Thematic analysis identified inadequate aftercare (21%), poor preoperative optimization (12%), and premature air travel (5%) as recurrent contributory factors. Estimated NHS treatment costs (5883- pound 9328 pound per patient) equated to 1.2 pound to 1.8 pound million over 2 years.Conclusions Cosmetic surgery tourism poses a substantial clinical and financial challenge for the NHS. A multilevel harm-reduction strategy-encompassing patient education, complication insurance, international accreditation, and data surveillance-is essential to improve safety and reduce preventable harm.
The multiple sclerosis community has made continuous improvements to historical diagnostic criteria by incorporating newer technology and recognising the need to diagnose MS at an early stage, when disease-modifying therapy may be more effective. Despite these improvements, we do not know how well these criteria perform in clinical practice. Therefore, a new approach may be needed going forward to incorporate lessons learned from other complex diseases to define the sensitivity and specificity of the criteria and to improve them. This is important to avoid misdiagnosis and overdiagnosis and, as a consequence, inappropriate treatment. We therefore propose a tiered process for developing and validating diagnostic criteria in the future. As part of this process, we suggest diagnostic criteria underpinned by a biological definition of MS, informed by deductive reasoning, and applying lessons learnt from other disease areas. In conclusion, we recommend that the MS community initiate a prospective international study to validate and compare MS diagnostic criteria. The ultimate aim is to facilitate the identification of individuals with early biological disease and to enhance overall diagnostic accuracy. It is important to develop a diagnostic framework for MS prevention that does not necessarily rely on clinical or radiological confirmation of MS, i.e., time to a first clinical or radiological event.
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterised by painful progressive skin ulceration. Medical management with corticosteroids and other immunomodulatory agents remains the mainstay of treatment. Surgical intervention has traditionally been avoided because of the risk of pathergy, whereby minor trauma progresses to ulceration. However, extensive or limb-threatening defects may necessitate reconstruction. We present a case of PG affecting the dorsum of the foot requiring free tissue transfer.
We report the case of a 12-year-old boy of Zimbabwean descent with coexistent Stickler and Noonan syndromes who was referred to our unit after being diagnosed with a macula-on inferior rhegmatogenous retinal detachment (RRD). His ophthalmic history was otherwise unremarkable. Systemic assessment revealed dysmorphic features consistent with both syndromes, and genetic testing confirmed heterozygous pathogenic variants in COL11A1 and PTPN11, inherited from the mother and father, respectively. The patient underwent multiple surgical interventions, including scleral buckling and pars plana vitrectomy with subretinal fluid drainage, laser retinopexy, and hexafluoroethane (C₂F₆) gas tamponade, ultimately achieving anatomical success and stable visual acuity at 11 months. To the best of our knowledge, this case is the first recorded coexistence of Stickler and Noonan syndromes in a patient with RRD, highlighting the significance of a multidisciplinary approach involving Ophthalmology, Genetics, and Paediatrics. Early detection of syndromic manifestation, comprehensive systemic evaluation, genetic diagnosis, and strategic surgical planning are essential to optimise functional and anatomical outcomes in paediatric patients with complex inherited vitreoretinal disorders.
BACKGROUND:Cosmetic surgery tourism has increased rapidly, with growing numbers of UK patients returning with complications requiring NHS care. Limited regulation and inconsistent perioperative standards contribute to preventable harm. OBJECTIVES:To characterise the nature, severity, and causes of complications from overseas cosmetic surgery and estimate the resulting burden on the NHS. METHODS:A national retrospective study analysed all 198 cases reported to the British Association of Aesthetic Plastic Surgeons (BAAPS) Cosmetic Tourism Complications Database between September 2022 and September 2024. Demographic, procedural, and clinical data were examined, and complications were graded using the BAAPS five-stage classification. RESULTS:Patients were predominantly female (93%) with a mean age of 39 years; 76% had surgery in Turkey. Abdominoplasty (45%) was the most common procedure, followed by breast and liposuction surgeries. Frequent complications included wound dehiscence (37%), infection (28%), seroma (24%), and tissue necrosis (20%). Nearly half (48%) required operative management under general anaesthesia, 28% minor procedures, and 4% intensive care; one death occurred from pulmonary embolism. Thematic analysis identified inadequate aftercare (21%), poor preoperative optimisation (12%), and premature air travel (5%) as recurrent contributory factors. Estimated NHS treatment costs (£5,883-£9,328 per patient) equated to £1.2-1.8 million over two years. CONCLUSIONS:Cosmetic surgery tourism poses a substantial clinical and financial challenge for the NHS. A multi-level harm-reduction strategy-encompassing patient education, complication insurance, international accreditation, and data surveillance-is essential to improve safety and reduce preventable harm.
